本研究旨在探讨聚球藻 7942 (Syne) 作为光声动力学疗法 (PSDT) 敏化剂的价值。对 Syne 进行了表征。 Syne 介导的 PSDT 的功效在体外（在 4T1 乳腺癌细胞中）和体内（在乳腺肿瘤小鼠模型中）得到验证。 Syne介导的PSDT的安全性已在体内得到验证。结果表明，Syne 在 PSDT 过程中触发氧气和 ROS 的产生，从而诱导 4T1 细胞死亡。 Syne介导的PSDT在体外和体内均诱导肿瘤细胞死亡。接受 PSDT 的动物肿瘤生长速度被延迟。同步介导的 PSDT 比单独的光动力疗法或声动力疗法更有效。此外，给予 Syne 单体可实现令人满意的肿瘤靶向。 Syne介导的PSDT既不影响动物体重，也不影响主要器官，表明安全性令人满意。因此，Syne 是一种高效、安全且易于获得的敏化剂，非常适合临床使用 PSDT 治疗乳腺癌。这项研究的结果有助于探索一种新型 PSDT 敏化剂，这可能是一种有前途的乳腺癌替代疗法。

This study was conducted to investigate the value of Synechococcus 7942 (Syne) as a sensitizer for photo-sonodynamic therapy (PSDT). Syne was characterized. The efficacy of Syne-mediated PSDT were verified in vitro (in 4T1 breast cancer cells) and in vivo (in a breast tumor-bearing mouse model). The safety of Syne-mediated PSDT was verified in vivo. Results indicated that Syne triggered the generation of oxygen and ROS during PSDT, thereby inducing cell death in 4T1 cells. Syne-mediated PSDT induced the death of tumor cells both in vitro and in vivo. The speed of tumor growth was delayed in animals receiving PSDT. Syne-mediated PSDT was more effective than photodynamic therapy or sonodynamic therapy alone. In addition, administration of a Syne monomer resulted in satisfactory tumor targeting. Syne-mediated PSDT affected neither the animal body weight nor the major organs, indicating satisfactory safety. Accordingly, Syne is an efficient, safe, and readily available sensitizer that is ideal for potential clinical use of PSDT to treat breast cancer. The findings of this study are useful for exploration of a novel sensitizer for PSDT, which might be a promising alternative therapy against breast cancer.